Eagle Pharmaceuticals, Inc (EGRX)

Etorro trading 970x250
Eagle Pharmaceuticals, Inc (EGRX) Logo

About Eagle Pharmaceuticals, Inc

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. Address: 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677

Eagle Pharmaceuticals, Inc News and around…

Latest news about Eagle Pharmaceuticals, Inc (EGRX) common stock and company :

Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin
18 Jan, 2022 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the commercial availability of its recently approved product, vasopressin, an A-rated generic alternative to Vasostrict®, with 180 days of marketing exclusivity. U.S. sales of Vasostrict totaled $890 million for the LTM ended September 30, 2021.1

Philips' (PHG) Q4 Earnings Hit By Supply-Chain Issues, Recall
12 Jan, 2022 Yahoo! Finance

Philips (PHG) fourth-quarter and 2021 results suffer from supply-chain constraints and adverse impact of the Respironics recall.

Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin
05 Jan, 2022 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update for 2022:

Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
03 Jan, 2022 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference as follows:

Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
29 Dec, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration has determined that the Company has maintained its 180 days of marketing exclusivity for its recently approved abbreviated new drug application (“ANDA”) for vasopressin. In August, the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company. An appeal of that decision remains pending.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
26 Dec, 2021 Yahoo! Finance

Eagle Pharmaceuticals (NASDAQ:EGRX) has had a great run on the share market with its stock up by a significant 9.0...

4 High Earnings Yield Stocks Likely to Pay Off Big Time
23 Dec, 2021 Yahoo! Finance

Summit Hotel (INN), Meritage Homes (MTH), Eagle Pharmaceuticals (EGRX) and BrightSphere (BSIG) could be some attractive bets if you are looking for high earnings yield picks.

Eagle Pharmaceuticals (EGRX) Upgraded to Buy: Here's What You Should Know
22 Dec, 2021 Yahoo! Finance

Eagle Pharmaceuticals (EGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin
20 Dec, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Par Pharmaceutical, Inc. (“Par”) has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product. Par’s appeal of the District Court’s ruling on August 31, 2021, that Eagle’s vasopressin product does not infringe any of the patents asserted by Par against Eagle remains pending, and Eagle will continue to vigorously defend against such appeal.

UPDATE 1-U.S. FDA approves Eagle’s generic version of Endo blood pressure drug
15 Dec, 2021 Yahoo! Finance

Eagle Pharmaceuticals Inc said on Wednesday the U.S. health regulator approved its generic version of Endo International's blood pressure drug, Vasostrict, sending its shares to a more than one-month high. The U.S. Food and Drug Administration's approval comes just months after a Delaware federal court ruled that Eagle's proposed generic, vasopressin, did not infringe on patents held by Endo subsidiary Par Pharmaceutical. Vasostrict brought in sales of more than $786 million last year, making it the Endo's best-selling drug.

Eagle Pharmaceuticals Receives FDA Approval for Vasopressin
15 Dec, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s abbreviated new drug application (“ANDA”) for vasopressin. This approval follows the recent U.S. District Court for the District of Delaware decision holding that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company.

The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
15 Dec, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 ...

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
12 Dec, 2021 FinancialContent

Biotech stocks closed out the week endingDec. 10 with modest losses as investors moved money out of defensives and into risky bets ...

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
02 Dec, 2021 FinancialContent

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, ...

Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
22 Nov, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021 as follows:

Eagle Pharmaceuticals (NASDAQ:EGRX) investors are sitting on a loss of 32% if they invested five years ago
11 Nov, 2021 Yahoo! Finance

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Eagle Pharmaceuticals, inc (EGRX) Q3 2021 Earnings Call Transcript
09 Nov, 2021 FinancialContent

EGRX earnings call for the period ending September 30, 2021.

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
09 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For ...

Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates
09 Nov, 2021 Yahoo! Finance

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -35.63% and -14.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals Reports Third Quarter 2021 Results
09 Nov, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2021.

Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021
28 Oct, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 third quarter financial results on Tuesday, November 9, 2021, before the market opens.

Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for
25 Oct, 2021 Yahoo! Finance

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
01 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
28 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

We Think Eagle Pharmaceuticals (NASDAQ:EGRX) Can Manage Its Debt With Ease
22 Sep, 2021 Yahoo! Finance

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021
07 Sep, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other guest speakers, to discuss the CAL02 opportunity, the current treatment landscape and the unmet medical need in treating patients with severe pneumonia as follows:

Eagle Pharmaceuticals to Present at September Healthcare Conferences
01 Sep, 2021 FinancialContent

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at two upcoming investor conferences as follows:

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
01 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Eagle Pharmaceuticals, Inc (EGRX) is a NASDAQ Common Stock listed in , ,

970x250